Extension study to evaluate the long term safety and efficacy of Bimatoprost ophthalmic solution 0.03% w/v compared with timolol 0.5% w/v ophthalmic solution for up to four years of dosing.

Trial Profile

Extension study to evaluate the long term safety and efficacy of Bimatoprost ophthalmic solution 0.03% w/v compared with timolol 0.5% w/v ophthalmic solution for up to four years of dosing.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 May 2017

At a glance

  • Drugs Bimatoprost (Primary) ; Timolol
  • Indications Glaucoma; Ocular hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top